WORK Medical Technology Group

WOK

Market cap $5.85M

Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a reverse stock split of its Class A ordinary shares of par value US$0.00001 each and Class B ordinary shares of par value US$0.00001 each at a ratio of 1-for-100, effective on June 18, 2026 (the “Reverse Stock Split”). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on June 18, 2026.

Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China,today announced its participation as a partner and exhibitor at the 2026 CBA-China Annual Conference (the “Conference”), held on May 8 to 10, 2026 in Wuxi, Jiangsu Province, China. The Conference was organized by the Chinese Biopharmaceutical Association China Branch (CBA-China) and co-hosted by BioValley, bringing together hundreds of scientists, entrepreneurs, and industry leaders from across the global biopharmaceutical sector.

Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its U.S. subsidiary, Work Bio Technologies Ltd (“WBT” or the “Subsidiary”), marking a strategic milestone in the Company's global expansion initiative and long-term growth strategy. In alignment with WORK Medical's long-term strategy to strengthen its global commercial operations and market development efforts, WBT will serve as the Company's primary operational platform in the United States.

Hangzhou, China, May 11, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiaries in China, today announced that it has entered into a strategic cooperation agreement (the “Agreement”) with Shanghai Novabioplus Biotechnology Co., Ltd. (“Novabioplus”), a provider of biological reagent products and solutions on April 13, 2026.

Hangzhou, China, May 01, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has been formally awarded a Council Member certificate as a Vice President Unit of Hong Kong Web3.0 Standardization Association Limited (the “Association”), an organization dedicated to standardization research in the Web3.0 sector.

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. (“Hunan Saitumofei”) has entered into a one-year exclusive distribution agreement (the “Agreement”) with Shanghai Benke Medical Technology Co., Ltd. (“Shanghai Benke”) to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the “Analyzer”) in East China throughout 2026. The collaboration is expected to accelerate market access and drive large-scale commercialization of the new product.

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's new AI-driven device as a key growth catalyst.

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125.

Hangzhou, China, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today is pleased to announce that its subsidiary, Neologics Bioscience Inc. (“Neologics”), has entered into a key service agreement (the “Agreement”) with GemPharmatech Corporation (“GemPharmatech”), a Delaware-based leading contract research organization.

Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an investment agreement (the “Investment Agreement”) with Neologics Bioscience Inc. (“Neologics”), a Delaware-based medical technology company specializing in research and development of medical technologies, with a focus on the integration of artificial intelligence and medicine (the “R&D”), to invest US$1 million in cash to acquire a 10% equity interest in Neologics.